Samsung Biologics has offered to buy 100% of PolyPeptide, a company that makes peptide-based medicines, for about CHF 1.46 billion in cash. Shareholders will receive CHF 44.31 for each share they own. The deal is expected to be completed by the end of 2026 if shareholders as well as regulators approve it. PolyPeptide's board has recommended that shareholders accept the offer as it believes the deal will aid the company to grow.
By buying PolyPeptide, Samsung Biologics will extend its business from making antibody medicines to also making peptide medicines, which are in high in demand for obesity, diabetes, cancer, and other diseases. PolyPeptide has over 70 years of experience and has produced more than 1,000 therapeutic peptides.
The acquisition will also support the global manufacturing network of Samsung Biologics. PolyPeptide has facilities in Sweden, Belgium, France, the United States, as well as India, along with its headquarters in Switzerland. Together, the two companies aim to offer a wider range of drug development and manufacturing services to customers around the world and support future growth.
As per Coherent Market Insights, the Biopharmaceutical Contract Manufacturing Market will grow at a 10.5% compound annual growth rate (CAGR) from 2026 to 2033, from USD 35.91 Bn in 2026 to around USD 72.24 Bn by 2033. The biopharmaceutical contract manufacturing market revenue is strongly propelled by multiple key growth drivers. Primary among these is the robust increase in biopharmaceutical R&D pipelines. Additionally, stringent regulatory frameworks enacted in North America and Europe ensure high-quality standards that Favor experienced CMOs, thereby amplifying market trust and growth.
"This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India," said John Rim, Chairman of the Board of Directors and CEO of Samsung Biologics. "We highly value PolyPeptide's world-class employees, industry-leading capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come."
"PolyPeptide was built on the dedication of our employees, deep scientific expertise and strong customer focus. After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics' offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today," said Peter Wilden, Chairman of the Board of Directors of PolyPeptide. "At the same time, it represents a transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics."
Source:
News: Samsung Biologics
